EGFR and esophageal squamous cell carcinoma: From the results of western blot assays, we found that lapatinib or gefitinib (EGFR and/or HER2 inhibitors) treatment alone could decrease the phosphorylation of EGFR and HER2 (lane 5 and lane 6) that was stimulated by EGF and IGF-1, and linsitinib (IGF-1R inhibitor) treatment alone could decrease the phosphorylation of IGF-1R (lane 7) in four ESCC cells.